One of the biggest challenges in cancer treatment is addressing the ability of cancer cells to adapt and become resistant, ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding ...

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and ...

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital  Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding ...

Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including ...

The sEVs, derived from natural killer (NK) cells, have demonstrated a remarkable ability to infiltrate tumors and selectively kill cancer cells expressing DR5. In murine models of melanoma, breast, ...

Researchers at the University of Pennsylvania have unveiled an innovative approach to cancer treatment that leverages tiny capsules known as small extracellular vesicles (sEVs). This experimental ...

1月23日，东南大学生命科学与技术学院、东南大学附属中大医院肿瘤科高山教授团队在Proceedings of the National Academy of Science of the United States of America杂志上发表了题为Complement C3 of Tumor-derived Extracellular Vesicles ...